An Analysis of Foot and Ankle Device Recalls by the Food and Drug Administration

Abstract

IntroductionOrthopaedic devices represent 12% of all medical device recalls. Products are approved through pre-market approval (PMA) or the 510(k) premarket notification process. No previous evaluation was found in the literature evaluating foot and ankle device recalls. The field of foot and ankle subspecialty has seen a rapid growth in innovation related to implants in recent years.MethodsThe Food and Drug Administration (FDA) Device Recall database was evaluated for all foot and ankle devices from 2007 through 2017 for the manufacturer, process of approval, type of implant, recall class, dates of initiation and termination of the recall, manufacturer determined reason, quantity affected, and distribution within the United States or internationally.ResultsA total of 161 products from 33 companies were identified with 158 (98.1%) approved through the 510(k) process. The most common reason for device recall was due to the device breaking intraoperatively or postoperatively. The average length of the recall was 487.5 days. ConclusionsDevice recall is not an uncommon event with the majority of products approved through the less demanding 510(k) process.

Evaluating the efficacy of bronchoscopy for the diagnosis of early stage lung cancer

“…Furthermore, this pathway does appropriately hasten the availability of new technology for patients suffering from serious disease states such as lung cancer. This potential disconnect between regulatory minimums, clinically important outcomes, and encouraging medical advances has recently come under scrutiny outside of the lung cancer space (16). Perhaps safety concerns are less relevant for new devices aimed at diagnosing lung cancer, but the motivations presented by 510(k) clearance will clearly affect new developments in bronchoscopy as all recent innovations in this technology have utilized this pathway (17).…”

El peligroso negocio con la salud (2018) y Salud a la venta (2018): denunciando la corrupción en la investigación biomédica

“…Este proceso pareciera ser menos riguroso y, si bien es centralizado, es proclive a «estropearse». De los dispositivos ortopédicos que por directriz de la misma FDA se han retirado del mercado, el 98% fueron aprobados por la vía 510(k) 4 , lo que señala una grave deficiencia en el proceso, que merita mayores estudios.…”

Impact of Design on Medical Device Safety

“…Among others, high-risk software-related recalls involved anesthesiology devices, such as ventilators and clinical decision support systems, with report details indicating that software shortcomings could result in a premature stoppage of mechanical ventilation. Recalls of infusion pumps intended to administer fluids to patients were also linked to software defects resulting in severe impairment of medication and fluids infusion [78][79][80][81]. The authors assert that having over 190,000 software units subject to high-risk recalls sets up a negative precedent, further aggravated by the impact of software such ABACUS TPN, which is intended for sustained use for large segments of the population without intermediate controls.…”